Chaim Hurvitz serves as Executive at NRX Pharmaceuticals, Inc., where they oversee executive responsibilities. Since joining the company, Chaim Hurvitz has executed 9 insider transactions totaling $1.1M, demonstrating a bullish approach to their equity position. Their most recent transaction on Aug 30, 2023 involved purchasing 70,000 shares valued at $20.3K.
Chaim Hurvitz currently holds 570,000 shares of NRX Pharmaceuticals, Inc. (NRXP), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Chaim Hurvitz has been a net buyer of NRXP stock. They have purchased $1.1M and sold $0 worth of shares.
Chaim Hurvitz's most recent insider trade was on Aug 30, 2023, when they purchased 70,000 shares at $0.29 per share.
Get notified when new Form 4 filings are submitted
| $1.10 |
| Discretionary |
| Nov 18, 2022 | NRXP | $44.4K | Purchase | 40,408 | $1.10 | Discretionary |
| Nov 17, 2022 | NRXP | $185.5K | Purchase | 171,780 | $1.08 | Discretionary |
| Nov 17, 2022 | NRXP | $185.5K | Purchase | 171,780 | $1.08 | Discretionary |
| Nov 16, 2022 | NRXP | $284.9K | Purchase | 287,812 | $0.99 | Discretionary |
| Nov 16, 2022 | NRXP | $284.9K | Purchase | 287,812 | $0.99 | Discretionary |
| May 24, 2021 | NRXP | $0 | Award | 208,443 | $N/A | Discretionary |
| May 24, 2021 | NRXP | $0 | Award | 1,436,350 | $N/A | Discretionary |